Geisinger joins collaboration to improve COPD outcomes with AI

Listen
Text
  • Small
  • Medium
  • Large

The COPD Foundation, pharmaceutical company GlaxoSmithKline, software provider Jvion and Danville, Pa.-based Geisinger Health System teamed up to help patients with chronic obstructive pulmonary disease avoid readmissions, Jvion announced Oct. 24.

The collaboration, funded by GSK, will apply Jvion's artificial intelligence solution to detect COPD inpatients at Geisinger who are at risk of a readmission within 30 days of discharge. The AI solution, called the "cognitive clinical success machine," uses data analytics to identify actions and medications — such as clinical trials — that may reduce patients' likelihood of readmission.

A second phase of the collaboration will involve identifying patients with COPD who are at risk for an avoidable hospitalization.

"GSK is committed to improving COPD disease management and we believe that the use of cognitive machine technology will improve our ability to assess the potential of novel therapies for individuals at risk of COPD hospital admission by selecting the right patients for clinical trials," said Ruth Tal-Singer, vice president of medicine development leader at GSK.

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars